...
首页> 外文期刊>Interventional cardiology. >Use of bivalirudin in patients receiving clopidogrel at the time of PCI for acute coronary syndromes
【24h】

Use of bivalirudin in patients receiving clopidogrel at the time of PCI for acute coronary syndromes

机译:比伐卢定在急性冠脉综合征PCI期间接受氯吡格雷治疗的患者中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

In the drive to improve outcomes with percutaneous coronary interventions (PCI), there has been an attempt to discover alternative anticoagulation strategies that improve efficacy and safety beyond unfraction-ated herparin (UFH). In the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial [1] and the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial [2], patients who were to undergo PCI for stable coronary syndromes and non-ST-segment elevation acute coronary syndromes (NSTE-ACS) were studied using bivalirudin versus UFH with glyco-protein Ilb/IIIa (Gp Ilb/IIIa) inhibitors.
机译:在通过经皮冠状动脉介入治疗(PCI)改善结局的努力中,已经尝试发现替代抗凝策略的方法,这些策略可以提高疗效和安全性,超越普通肝素(UFH)。在将PCI链接的Angiomax减少临床事件的随机评估(REPLACE-2)试验[1]和急性导管插入和紧急干预分类策略(ACUITY)试验[2]中,因稳定的冠状动脉综合征而接受PCI治疗的患者使用比伐卢定与UFH结合糖蛋白Ilb / IIIa(Gp Ilb / IIIa)抑制剂研究了-ST段抬高的急性冠状动脉综合征(NSTE-ACS)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号